Difference between revisions of "Vortioxetine-nortriptyline"

From Psychiatrienet
Jump to: navigation, search
Line 7: Line 7:
 
{{washout8-14}}
 
{{washout8-14}}
 
* '''Day 15:''' start administration of nortriptyline in a low dosage of 25 mg/day.
 
* '''Day 15:''' start administration of nortriptyline in a low dosage of 25 mg/day.
{{Day22NoBloodlevelvortioxetine}}
+
{{Day22NoBloodlevelvortioxetine}} <ref name="vortiswitch"> {{Pubmed|24570588 |Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54}}</ref> <ref name="informatorium">{{KNMP|vortioxetine}}</ref>
  
 
|info =  
 
|info =  
 
* {{theorSS}}
 
* {{theorSS}}
 
}}
 
}}

Revision as of 15:15, 4 November 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Nortriptyline
Type Antidepressant
Group TCA
links
Medscape Nortriptyline
PubChem 4543
PubMed Nortriptyline
Kompas (Dutch) Nortriptyline
Wikipedia Nortriptyline

Switch medication from vortioxetine to nortriptyline.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 8: stop administration of vortioxetine.
Eenrichtingbord.png Start nortriptyline
  • Day 8-14: a wash-out period of 1 week is necessary.
  • Day 15: start administration of nortriptyline in a low dosage of 25 mg/day.
  • Day 22: bloodlevel vortioxetine is now zero, so you can increase faster. [3] [4]
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Katona et al. New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder. 2014 2014 Feb 19;10:349-54
  4. KNMP; Informatorium Medicamentorum 2023; Monografie "vortioxetine" (Dutch)
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.